跳至主要内容
临床试验/NCT07610226
NCT07610226招募中不适用

Post-refractive IOL Outcomes With Clareon TruPlus

Laser Defined Vision1 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2026年6月25日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
35
试验地点
1

研究概览

简要总结

This is a prospective, single-arm, single-center, single-surgeon study evaluating the Clareon TruPlus IOL in post-refractive cataract patients. Subjects will be assessed up to 3 months post-operatively. Clinical evaluations will include refractive outcomes, visual acuity, and administration of the PRISQ Questionnaire.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Willing and able to understand and sign informed consent.
  • Adult patients (>45 years old) undergoing age-related cataract surgery that previously had myopic corneal refractive surgery.
  • Dominant eye targeted for emmetropia, non-dominant eye may be targeted for ≤-0.75D (mini-monovision).
  • Best monocular corrected distance visual acuity expected to be 0.1 logMAR (Snellen 20/25) or better in both eyes pre-operatively as determined by surgeon.
  • Normal ocular findings aside from cataract.

排除标准

  • Moderate-severe corneal pathology, irregular astigmatism, preexisting macular disease and other retinal degenerative diseases, diabetic retinopathy that is expected to cause future vision loss, glaucoma, severe dry eye disease, nystagmus, strabismus, zonular laxity or dehiscence, pseudoexfoliation.
  • Previous history of any ocular surgery, except for myopic LASIK or PRK.
  • Previous hyperopic refractive surgery.
  • Corneal HOA ≥1.0 µm (RMS) with OPD at 4mm scan.
  • Any active ocular infection or inflammation.

研究组 & 干预措施

Clareon TruPlus

干预措施: Clareon TruPlus (Device)

研究者

发起方
Laser Defined Vision
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验